Table 1.
Results of neoadjuvant immunotherapy and combined chemotherapy/immunotherapy trials in resectable non‐small cell lung cancer
| Rx | n | mPR, n (%) | pCR, n (%) | Ref |
|---|---|---|---|---|
| Nivolumab | 21 | 9 (43) | 3 | 60 |
| Nivolumab or nivolumab + ipilimumab | 44 | 11/41 (25) | 8 (18) | 61 |
| Atezolizumab | 82 | 15 (18) | 4 (5) | 62 |
| Sintilimab | 22 | 10 (45) | 4 (18) | 63 |
| Pembrolizumab | 10 | 4 (40) | 0 | 64 |
| Total I/O alone | 179 | 49 (27) | 19/176 (11) | |
| Nivolumab + CT | 30 | 24 (80) | 13 (60) | 65 |
| Atezolizumab + CT | 30 | 17 (57) | 10 (33) | 66 |
| Nivolumab + CT | 13 | 11 (85) | 5 (38) | 67 |
| Durvalumab + CT | 67 | 33 (60) | 10 (18) | 68 |
| Total I/O + CT | 140 | 85 (61) | 38 (27) |
Abbreviations: CT, chemotherapy; I/O, immunotherapeutic; mPR, major pathologic response; n, number; NR, not reported; pCR, pathologic complete response; Ref, reference; Rx, treatment.